| Ryan Ya Nomura, MD | |
|
226 N Kuakini St, Honolulu, HI 96817-2421 | |
| (808) 544-3325 | |
| Not Available |
| Full Name | Ryan Ya Nomura |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 21 Years |
| Location | 226 N Kuakini St, Honolulu, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588861272 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 14441 (Hawaii) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rehab Associates Of The Pacific Llc | 6608190822 | 8 |
| Rehabilitation Hospital Of The Pacific | 9436068442 | 7 |
News Archive
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.
Bottom Line: Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.
Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.
Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account.
Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.
› Verified 9 days ago
| Entity Name | Ryan Y A Nomura Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710160262 PECOS PAC ID: 0840377370 Enrollment ID: O20080409000084 |
News Archive
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.
Bottom Line: Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.
Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.
Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account.
Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.
› Verified 9 days ago
| Entity Name | Rehab Associates Of The Pacific Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114322880 PECOS PAC ID: 6608190822 Enrollment ID: O20150117000100 |
News Archive
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.
Bottom Line: Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.
Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.
Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account.
Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.
› Verified 9 days ago
| Entity Name | Rehabilitation Hospital Of The Pacific |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1730580424 PECOS PAC ID: 9436068442 Enrollment ID: O20150311001024 |
News Archive
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.
Bottom Line: Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.
Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.
Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account.
Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Ya Nomura, MD 2855 E Manoa Rd Ste 105, Box #200, Honolulu, HI 96822 Ph: (808) 941-6300 | Ryan Ya Nomura, MD 226 N Kuakini St, Honolulu, HI 96817-2421 Ph: (808) 544-3325 |
News Archive
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain.
Bottom Line: Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.
Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.
Numerous studies have documented the favorable effects of MARS albumin dialysis treatment on clinical and laboratory parameters and survival in liver failure patients. However, to ensure that limited resources are utilized in an ethical manner, the subjective feelings of the patient in terms of health-related quality of life and costs should also be taken into account.
Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.
› Verified 9 days ago
Won-yee Cheng-leever, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2828 Paa St, Honolulu, HI 96819 Phone: 808-432-5777 | |
Dr. Maria B. Patten, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2828 Paa St, Honolulu, HI 96819 Phone: 808-432-7450 | |
Dr. Timothy Joseph Roe, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 226 N Kuakini St, Honolulu, HI 96817 Phone: 808-566-3471 | |
Dr. Daniel Shawn Burdick, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 226 N Kuakini St, Honolulu, HI 96817 Phone: 808-531-3511 | |
Miss Diana Mun Wah Lee, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 226 N Kuakini St, Honolulu, HI 96817 Phone: 808-544-3310 | |
April Michelle Brewster, LPTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 615 Piikoi St, Honolulu, HI 96814 Phone: 808-591-6068 | |
Dr. Amendeep K Somal, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 226 N Kuakini St, Honolulu, HI 96817 Phone: 808-566-3460 Fax: 808-535-1572 |